by RFMP assay of stored frozen serum, and direct sequencing was also conducted for more accurate genotyping in cases with heterozygous alleles.
Modification of treatment
The peginterferon dosage was reduced if leukocyte counts decreased to ≤1,000/mm 3 or if neutrophil counts decreased to ≤750/mm 3 , treatment discontinuation was considered if neutrophil counts decreased to ≤500/mm 3 . In addition, peginterferon dosage was reduced if platelet counts decreased to ≤50,000/mm 3 ; treatment discontinuation was considered if counts decreased to ≤25,000/mm 3 . For anemia with hemoglobin levels ≤10 g/dL, ribavirin dosage was reduced and administration of erythropoietin was considered; for anemia with hemoglobin levels ≤8.0 g/dL, ribavirin discontinuation was considered.
Definition of virological response
Rapid virological response (RVR) were defined as negative for HCV RNA at treatment week 4; early virological response (EVR) was defined as ≥2 log IU/mL reduction in HCV RNA levels or negative for HCV RNA at treatment week 12. End-of-treatment response (ETR) was defined as HCV RNA negative at the end of treatment; sustained virological response (SVR) was defined as undetectable levels of HCV RNA 24 weeks after treatment cessation. In addition, complete EVR (cEVR) was defined as negativity for HCV RNA during EVR.
Baseline characteristics
Patients with cirrhosis were older than those without cirrhosis, regardless of their HCV genotype, and they showed lower serum albumin levels, lower platelet counts, higher serum bilirubin levels, and longer prothrombin time (all p<0.05). Among patients without cirrhosis, the proportion of women was higher for those with non-1 HCV genotypes than the genotype 1 group, which probably resulted in lower mean hemoglobin levels in those with non-1 HCV genotypes (Table 1) .
Results of virological response
Among 103 patients with HCV genotype 1 without cirrhosis, RVR was attained in 51% (42/82), EVR in 80%, cEVR in 75%, ETR in 79%, and SVR in 67%. Among 49 patients with HCV genotype 1 with cirrhosis, RVR was reached in 35% (15/43), EVR in 76%, cEVR in 71%, ETR in 74%, and SVR in 37%. Among 109 patients with non-1 HCV genotypes and without cirrhosis, RVR was achieved in 90% (83/92), EVR in 94%, cEVR in 92%, ETR in 95%, and SVR in 86% of patients. Among 43 patients with non-1 HCV genotypes and cirrhosis, RVR was accomplished in 83% (30/36), EVR in 97%, cEVR in 88%, ETR in 95%, and SVR in 86% of patients. For all categories of virological response, the rates of achievement were significantly lower in patients with HCV genotype 1 than that in those with non-1 genotypes for patients with and without cirrhosis. Among patients with genotype 1, the rates of virological responses were significantly lower in those with cirrhosis than those without (p<0.001), while there was no significant difference between those with and without cirrhosis among patients with non-1 genotypes (Table 1) .
